1. Pfizer. Pfizer and BioNTech conclude phase 3 study of COVID-19 vaccine candidate, meeting all primary efficacy endpoints. 2020 Nov 18 [cited 2020 Nov 25]. https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-conclude-phase-3-study-covid-19-vaccine.
2. Moderna. Moderna’s COVID-19 vaccine candidate meets its primary efficacy endpoint in the first interim analysis of the phase 3 COVE study. 2020 Nov 16 [cited 2020 Nov 25]. https://investors.modernatx.com/news-releases/news-release-details/modernas-covid-19-vaccine-candidate-meets-its-primary-efficacy.
3. AstraZeneca. AZD1222 vaccine met primary efficacy endpoint in preventing COVID-19. 2020 Nov 23 [cited 2020 Nov 25]. https://www.astrazeneca.com/media-centre/press-releases/2020/azd1222hlr.html.
4. Reserving coronavirus disease 2019 vaccines for global access: cross sectional analysis
5. Global, regional, and national estimates of target population sizes for covid-19 vaccination: descriptive study